Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2007

View Archived Issues

Positive results for Regeneron's proof-of-concept study of rilonacept for gout / News in Context

Novel CXCR2 antagonist useful in models of acute and chronic inflammation

GenVec signs CRADA for malaria vaccine development

ProMetic Life Sciences expands PBI-1402 program to include cancer-related anemia

Positive results for Renovo's phase II trial of Juvista for treatment of wounds and scars

New antipsychotic, antidepressive and anxiolytic agents cited in patent literature

CRT, UCL and Novozymes to codevelop novel anticancer therapeutics

FDA opens Corcept's IND for Corlux for Cushing's syndrome allowing initiation of phase III study

Estrogen-dependent breast cancer growth in vivo suppressed by KW-2581

New compounds for treatment of HCV infection revealed

Recent patents impart new therapeutic agents for cancer

FDA Advisory Committees reaffirm current dosing practices for ESAs

Inhibitex licenses HIV integrase and hepatitis C polymerase inhibitors from UGARF

Phenomix begins phase IIb trial of PHX-1149 for type 2 diabetes

Phosphagenics to initiate phase II trials of TMP/Insulin for diabetes

BioSante and FDA reach agreement on LibiGel development requirements

Update on Aspreva and Roche's development of CellCept for lupus nephritis

Nventa begins phase I trial of HspE7 dosed with an adjuvant for CIN

Positive results for Chelsea's new formulation of CH-1504 for RA

Trubion reports preliminary analysis of phase IIb trial of TRU-015 for RA

New drug targets in neuropathic pain described

Minocycline shows neuroprotection in animal models of Alzheimer's disease

Pivotal phase III prophylactic HAE trial of Cinryze meets primary endpoint

FDA grants Metabasis' MB-07133 orphan drug designation for HCC

Novartis launches daptomycin for MSSA and MRSA bloodstream and heart infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...